Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
At Creative Biolabs, our innovative CAR-T products are of high quality and are designed to support research and development efforts in the field of cancer immunotherapy. Our anti-IGFBP2 CAR products are carefully designed and manufactured to target IGFBP2.
Insulin-like growth factor binding protein 2 (IGFBP2) is a protein that plays a crucial role in regulating the activity of insulin-like growth factors (IGFs), which are important for cell growth, proliferation, and survival. Research has shown that IGFBP2 may play a role in cancer, as it has been found to be overexpressed in certain types of tumors, including glioblastoma, breast cancer, and prostate cancer. Although still in the early stages of development, targeting IGFBP2 therapy holds promise as a potential treatment strategy for cancer and other diseases. By targeting IGFBP2, researchers aim to inhibit its pro-tumorigenic effects, potentially slowing down tumor growth, preventing metastasis, and improving the overall prognosis of cancer patients.
Fig.1 Schematic of IGFBP2.1
Associated Disease
The anti-IGFBP2 CAR-T expression test plays a crucial role in monitoring and optimizing CAR-T cell therapy. Our anti-IGFBP2 CAR-T expression test typically involves analyzing the expression level of the CAR on the surface of T cells using flow cytometry or other molecular techniques.
The CAR-T proliferation test is essential in evaluating the functionality and efficacy of CAR-T therapy in the treatment of various cancers. We provide anti-IGFBP2 CAR-T proliferation test service to measure the growth and expansion of CAR-T cells through techniques such as flow cytometry, cell counting, and cell viability assays.
At Creative Biolabs, our scientists utilize techniques, like ELISA or multiplex cytokine assays to measure the released levels of various cytokines, such as interleukin-6 (IL-6), interleukin-10 (IL-10), tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), and others.
CAR-T cytotoxicity tests are essential to assess the effectiveness and safety of CAR-T cell therapy. We perform several different types of in vitro CAR-T cell cytotoxicity assays such as Chromium-51 release assay, LDH release assay, and flow cytometry-based cytotoxicity assays.
In vivo assays can provide valuable information on the efficacy, safety, and potential side effects of CAR-T cell therapies before they are tested in clinical trials in humans. We provide a variety of in vivo assays to monitor and assess anti-tumor efficacy of anti-IGFBP2 CAR-T cells.
Reference
Loading...
| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
| CAR-CN017 | Anti-IGFBP2 (10B4) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 10B4 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CN018 | Anti-IGFBP2 (1B4) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 1B4 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CN019 | Anti-IGFBP2 (1H12) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 1H12 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CN020 | Anti-IGFBP2 (5D1) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 5D1 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CN021 | Anti-IGFBP2 (5F5) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 5F5 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CN022 | Anti-IGFBP2 (6D11) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 6D11 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CN023 | Anti-IGFBP2 (7G8) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 7G8 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CN024 | Anti-IGFBP2 (8G8) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 8G8 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CN025 | Anti-IGFBP2 (9A6) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 9A6 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CN026 | Anti-IGFBP2 (9D9) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 9D9 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CN118 | Anti-IGFBP2 (10B4) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 10B4 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CN119 | Anti-IGFBP2 (1B4) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 1B4 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CN120 | Anti-IGFBP2 (1H12) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 1H12 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CN121 | Anti-IGFBP2 (5D1) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 5D1 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CN122 | Anti-IGFBP2 (5F5) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 5F5 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CN123 | Anti-IGFBP2 (6D11) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 6D11 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CN124 | Anti-IGFBP2 (7G8) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 7G8 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CN125 | Anti-IGFBP2 (8G8) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 8G8 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CN126 | Anti-IGFBP2 (9A6) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 9A6 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-CN127 | Anti-IGFBP2 (9D9) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 9D9 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
